concerns persist about the 340b program

3
6/2/16, 4:52 PM Concerns Persist about the 340B Program Page 1 of 3 http://www.pharmacytimes.com/news/concerns-persist-about-the-340b-program Login | Register | Subscribe PRACTICE SETTING Concerns Persist about the 340B Program Nan Myers Published Online: Tuesday, May 31, 2016 Did you know there is a federal program that provides medicines at a steep discount to some hospitals and clinics? Created in 1992 as part of the Veterans Health Care Act, the 340B drug pricing program requires drug companies to provide discounts—sometimes as much as 50%—to covered entities, hospitals, and clinics that treat low-income and uninsured patients. Covered entities also include federally qualified health centers and look-alikes, consolidated health centers, freestanding cancer centers, and more. In addition to paying less for the drugs, the covered entities are also permitted to generate profits from the sale of prescription medications to insured patients in order to subsidize required medications for underinsured patients. Under the 340B program, participating drug manufacturers sign an agreement with the Department of Health and Human Services (HHS) stipulating that they will charge covered entities at or below a maximum price, known as the ceiling price. Pharmacy Services Typically, pharmacy services provided by a 340B-covered entity may be provided through either an in-house pharmacy or a contract with an outside pharmacy, including a community pharmacy. The thinking is that a community pharmacy might provide real value to a patient and also add an income stream to its existing business model. 1 That is not necessarily so according to a white paper 2 “The 340B law’s legislative history makes clear that the intent of the 340B program is to help uninsured indigent patients by giving covered entities that serve high numbers of uninsured indigent patients access to discounts for drugs. Today, however, it is unclear whether this goal is being met even as the program continues to grow dramatically. Evidence suggests that the program has departed significantly from its statutory foundation.” Medical centers, hospitals, and other covered entities have begun to use the program to boost profits rather than help low-income and uninsured patients. Over the past few years, there have been calls for greater oversight of the program due to complaints that some hospitals are receiving discounted drug benefits disproportional to the small number of low-income patients they serve. “Hospitals participating in the 340B program aren't required to pass the discount along to patients or insurers and can subsequently turn a profit by charging the full price for medications the hospital bought at a discount,” according to an article published by Becker’s Hospital CFO. 1 The study discussed in the article was conducted by Rena Conti, PhD, an assistant professor of health policy and economics in the University of Chicago Departments of Pediatrics and Health Studies, and Peter Bach, MD, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. They analyzed data from 960 hospitals and 3964 affiliated clinics registered for the 340B program in 2012, along with socioeconomic information on the communities those hospitals and clinics served from the US Census Bureau's American Community Survey. “Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics,” they write in the study. 1 More Questions The Health Resource and Service Administration’s (HRSA) 2010 guidance, which allowed hospitals to use an unlimited number of neighborhood pharmacies to fill 340B prescriptions, was premised on the expectation that entities contracting with multiple pharmacies would not increase the risk of 2 illegal activities: (1) diversion of 340B medicines to persons who are not eligible to receive them, and (2) permitting manufacturers to be charged duplicate Medicaid and 340B discounts for the same drug. HRSA further assumed that entities contracting with multiple pharmacies would adhere to certain program integrity standards. Independent reports by the Government Accounting Office and the HHS Office of Inspector General call into question whether these expectations are being met. 3 One issue is that the program allows News Videos Resource Centers Continuing Education Community Publications

Upload: nan-myers

Post on 28-Jan-2018

134 views

Category:

Documents


0 download

TRANSCRIPT

6/2/16, 4:52 PMConcerns Persist about the 340B Program

Page 1 of 3http://www.pharmacytimes.com/news/concerns-persist-about-the-340b-program

Login | Register | Subscribe

PRACTICE SETTING

Concerns Persist about the 340B ProgramNan MyersPublished Online: Tuesday, May 31, 2016

Did you know there is a federal program that provides medicines at a steep discount to some hospitals andclinics? Created in 1992 as part of the Veterans Health Care Act, the 340B drug pricing program requiresdrug companies to provide discounts—sometimes as much as 50%—to covered entities, hospitals, andclinics that treat low-income and uninsured patients.

Covered entities also include federally qualified health centers and look-alikes, consolidated health centers,freestanding cancer centers, and more. In addition to paying less for the drugs, the covered entities are alsopermitted to generate profits from the sale of prescription medications to insured patients in order tosubsidize required medications for underinsured patients. Under the 340B program, participating drugmanufacturers sign an agreement with the Department of Health and Human Services (HHS) stipulating thatthey will charge covered entities at or below a maximum price, known as the ceiling price. Pharmacy Services Typically, pharmacy services provided by a 340B-covered entity may be provided through either an in-housepharmacy or a contract with an outside pharmacy, including a community pharmacy. The thinking is that acommunity pharmacy might provide real value to a patient and also add an income stream to its existing

business model.1That is not necessarily so according to a white paper2…

“The 340B law’s legislative history makes clear that the intent of the 340B program is to help uninsuredindigent patients by giving covered entities that serve high numbers of uninsured indigent patients access todiscounts for drugs. Today, however, it is unclear whether this goal is being met even as the programcontinues to grow dramatically. Evidence suggests that the program has departed significantly from itsstatutory foundation.”

Medical centers, hospitals, and other covered entities have begun to use the program to boost profits ratherthan help low-income and uninsured patients. Over the past few years, there have been calls for greateroversight of the program due to complaints that some hospitals are receiving discounted drug benefitsdisproportional to the small number of low-income patients they serve.

“Hospitals participating in the 340B program aren't required to pass the discount along to patients orinsurers and can subsequently turn a profit by charging the full price for medications the hospital bought at a

discount,” according to an article published by Becker’s Hospital CFO.1

The study discussed in the article was conducted by Rena Conti, PhD, an assistant professor of healthpolicy and economics in the University of Chicago Departments of Pediatrics and Health Studies, and PeterBach, MD, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering CancerCenter. They analyzed data from 960 hospitals and 3964 affiliated clinics registered for the 340B program in2012, along with socioeconomic information on the communities those hospitals and clinics served from theUS Census Bureau's American Community Survey.

“Our findings support the criticism that the 340B program is being converted from one that serves vulnerable

patient populations to one that enriches hospitals and their affiliated clinics,” they write in the study.1

More QuestionsThe Health Resource and Service Administration’s (HRSA) 2010 guidance, which allowed hospitals to usean unlimited number of neighborhood pharmacies to fill 340B prescriptions, was premised on theexpectation that entities contracting with multiple pharmacies would not increase the risk of 2 illegalactivities: (1) diversion of 340B medicines to persons who are not eligible to receive them, and (2) permittingmanufacturers to be charged duplicate Medicaid and 340B discounts for the same drug. HRSA furtherassumed that entities contracting with multiple pharmacies would adhere to certain program integritystandards. Independent reports by the Government Accounting Office and the HHS Office of Inspector

General call into question whether these expectations are being met.3One issue is that the program allows

News Videos Resource Centers Continuing Education Community Publications

6/2/16, 4:52 PMConcerns Persist about the 340B Program

Page 2 of 3http://www.pharmacytimes.com/news/concerns-persist-about-the-340b-program

hospitals to use the discounted drugs to treat not only poor patients but also those covered by Medicare orprivate insurance.

The Berkeley Research Group conducted an analysis of the 2014 contract pharmacy network of 10hospitals in 10 different cities that participate in 340B, based on their disproportionate share hospitalpercentage and their having 50 or more contract pharmacies. The location of each contract pharmacy wasclassified by the median income of the zip code tabulation area in which the pharmacy was located. Amongthese 10 hospitals’ contract pharmacy networks, 1050 pharmacies were identified. The analysis found thereare many more contract pharmacies in areas with median incomes above 400% of the poverty level than ator below 200% of the poverty level. Of the 1050 contract pharmacies, only 16% were located in areas with a

median income at or below 200% of the poverty level for a family of 3.3

Contract PharmaciesThe irony of the contract pharmacy program is that it is supposed to make it more convenient for patients ofcovered entities to access 340B drugs, but that does not mean that pharmacies provide such patients withdiscounts on drugs purchased under the 340B program. Insured patients of covered entities do not benefitfrom 340B prices when their prescriptions are filled by contract pharmacies—health plans pay pharmaciesthe rate established by agreement between the plan or its pharmacy benefit manager and the pharmacy.And although uninsured patients often receive free or discounted drugs from covered entities’ in-housepharmacies, retail pharmacies typically charge cash payers a higher rate than their insured customers.Consequently, the most vulnerable patients of covered entities may pay more when they take their

prescriptions to their community pharmacies.4

It may be that passing 340B savings to uninsured patients can create operational challenges for contractpharmacies; these pharmacies are also commercial ventures and may have little business reason to adjusttheir operations to identify 340B prescriptions before the drugs are dispensed. Pharmacies often participatein this program only to the extent that the administrative fee or share of the resale price for 340B drugs(deducted from the amount remitted to the covered entity) is more profitable than the sale of their own stock.For example, contract pharmacy arrangements sometimes omit prescriptions of generic drugs because theretail margin over cost is greater than brand drugs. As a result, the parties to contract pharmacyarrangements may profit more on the resale of 340B drugs to an uninsured patient—who is charged ahigher cash rate—than they would on the resale to a patient covered by insurance, which pays the

pharmacy a lower negotiated rate.4

So often, a program is created that seems to be doing the right thing for the right people. And yet, so often,we find that although the intent was a good one, the implementation enables chicanery or more. The 340Bprogram is a prime example.

As we go to press, the Medicare Payment Advisory Commission (MedPac) has been proposing changes toCongress that will include pay rates for hospitals and clearly defining which patients are eligible for 340Bdrugs.

A corporate and magazine scribe, Nan Myers writes frequently about health care.

References

1. Adamopoulos H. Are hospitals abusing the 340B drug discount program? new study reignitescontroversy. Becker’s Hospital CFO website. beckershospitalreview.com/finance/are-hospitals-abusing-the-340b-drug-discount-program-new-study-reignites-controversy.html. Published October 7,2014. Accessed May 19, 2016.

2. The 340B Discount Program. ncpanet.org/pdf/leg/feb13/340b_white_paper.pdf. Published winter2013. Accessed May 19, 2016.

3. The impact of growth in 340B contract pharmacy arrangements. The Alliance for Integrity and Reformof 340B (AIR 340B) website.340breform.org/userfiles/FINAL.The%20Impact%20of%20Growth%20in%20340B%20Contract%20Pharmacy%20Arrangements.%20AIR%20340B.%20July%2014,%202014.pdf.Published Summer 2014. Accessed May 19, 2016.

4. Yesner DL. HHS OIG reports findings on 340B contract pharmacy program. Morgan Lewis website.morganlewis.com/pubs/lifesci_lf_hhsoigreportsfindingsof340bcontractpharmprgm_18feb14#sthash.WtlmaO1Q.0gCsgP2Q.dpuf.Published February 18, 2014. Accessed May 19, 2016.

Tweet your thoughts about this article @Pharmacy_Times

Join the conversation on the Pharmacy Times Facebook page

Sign up for our eNews to get the latest news and updates delivered to your inbox

6/2/16, 4:52 PMConcerns Persist about the 340B Program

Page 3 of 3http://www.pharmacytimes.com/news/concerns-persist-about-the-340b-program

MJH AssociatesAmerican Journal of Managed CareCureMD MagazineONCLiveOTCGuideSpecialty Pharmacy TimesTargeted Oncology

About UsCareersContact UsFeedbackAdvertise With UsTerms & ConditionsPrivacyPress Room

Intellisphere, LLC666 Plainsboro RoadBuilding 300Plainsboro, NJ 08536P: 609-716-7777F: 609-257-0701

Copyright PharmacyTimes 2006-2016Pharmacy & Healthcare Communications, LLC.All Rights Reserved.

Latest Issues